Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease

An isolated primer pair, comprising the pair of nucleic acid sequences selected from the group consisting of:

• SEQ NOs 61 and 62;
• 64 and 274;
• 276 and 277;
• 279 and 280;
• 336 and 337;
• 363 and 364;
• 366 and 367;
• 369 and 370;
• 374 and 375;
• 377 and 378;
• 380 and 381;
• and 383 and 384.

An isolated polypeptide comprising the polypeptide sequence set forth in a member selected from the group consisting of 281-334, 394-436 and 454-458, or the polypeptide sequence at least about 95% homologous thereto, or from the group consisting of:

• the polypeptide comprising a first amino acid sequence of amino acids 1-124 of SEQ ID NO. 301, and a second amino acid sequence being at least 95% about homologous to amino acids 125-137 of SEQ ID NO. 301, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-8 of SEQ ID NO. 302, and a second amino acid sequence being at least 95% about homologous to amino acids 9-182 of SEQ ID NO. 302, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-36 of SEQ ID NO. 303, and a second amino acid sequence being at least 95% about homologous to amino acids 37-86 of SEQ ID NO. 303, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-8 of SEQ ID NO. 304, and a second amino acid sequence being at least about 95% homologous to amino acids 9-13 of SEQ ID NO. 304, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise AK, having a structure as follows:
• starting from any of amino acid numbers 8−x to 8 of SEQ ID NO:
• 302;
• and ending at any of amino acid numbers 9+((n−2)−x) of SEQ ID NO:
• 302, in which x varies from 0 to n−2;
• the isolated peptide comprising the amino acid sequence set forth in a 50 amino acid long segment of SEQ ID NO:
• 302 anywhere from amino acid position 1 to amino acid position 58, and including amino acids at positions 8 and 9;
• the isolated peptide comprising the amino acid sequence set forth in a 40 amino acid long segment of SEQ ID NO:
• 302 anywhere from amino acid position 1 to amino acid position 48, and including amino acids at positions 8 and 9;
• the isolated peptide comprising the amino acid sequence set forth in a 30 amino acid long segment of SEQ ID NO:
• 302 anywhere from amino acid position 1 to amino acid position 38, and including amino acids at positions 8 and 9;
• the isolated peptide comprising the amino acid sequence set forth in a 20 amino acid long segment of SEQ ID NO:
• 302 anywhere from amino acid position 1 to amino acid position 28, and including amino acids at positions 8 and 9;
• the polypeptide comprising a first amino acid sequence of amino acids 1-1855 of SEQ ID NO.326, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1856-1904 of SEQ ID NO. 326, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-1326 of SEQ ID NO.327 and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1327-1336 of SEQ ID NO. 327, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-1508 of SEQ ID NO.328 and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1509-1534 of SEQ ID NO. 328, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-1763 of SEQ ID NO.329 and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1764-1788 of SEQ ID NO. 329, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1-22 of SEQ ID NO.330 and a second amino acid sequence of amino acids 23-1434 of SEQ ID NO. 330, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-527 of SEQ ID NO.339 and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 528-555 of SEQ ID NO.331, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-1798 of SEQ ID NO.332, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1799-1847 of SEQ ID NO.332, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-156 of SEQ ID NO.318, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 157-166 of SEQ ID NO.318, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-156 of SEQ ID NO.319, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 157-210 of SEQ ID NO.319, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-60 of SEQ ID NO. 320, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 61-114 of SEQ ID NO. 320, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-14 of SEQ ID NO. 321, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 15-87 of SEQ ID NO. 321, wherein said first amino acid sequence and second amino acid sequence amino acids 15-87 of SEQ ID NO. 321, wherein said first amino acid sequence and second amino acid sequence
• the polypeptide comprising a first amino acid sequence of amino acids 1-60 of SEQ ID NO.324, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 61-70 of SEQ ID NO.324, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-184 of SEQ ID NO. 314, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 185-197 of SEQ ID NO. 314, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-151 of SEQ ID NO. 315, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 152-177 of SEQ ID NO. 315, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-657 of SEQ ID NO. 309, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 658-708 of SEQ ID NO. 309, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-676 of SEQ ID NO. 310, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 677-685 of SEQ ID NO. 310, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-657 of SEQ ID NO. 311, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 658-696 of SEQ ID NO. 311, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-294 of SEQ ID NO. 308, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 295-304 of SEQ ID NO. 308, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-116 of SEQ ID NO. 281, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 117-215 of SEQ ID NO. 281, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-116 of SEQ ID NO. 282, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 117-178 of SEQ ID NO. 282, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-203 of SEQ ID NO. 285, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 204-240 of SEQ ID NO. 285, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-78 of SEQ ID NO. 286, a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 79-125 of SEQ ID NO. 286, and a third amino acid sequence of amino acids 126-446 of SEQ ID NO. 286, wherein said first, second and third amino acid sequences are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 1-15 of SEQ ID NO. 289, and a second amino acid sequence of amino acids 16-212 of SEQ ID NO. 289, wherein said first amino acid sequence and second amino acid sequence are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-374 of SEQ ID NO. 295, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 375-390 of SEQ ID NO. 295, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the polypeptide comprising a first amino acid sequence of amino acids 1-36 of SEQ ID NO. 303, and a second amino acid sequence being at least about 95% homologous to a polypeptide sequence corresponding to amino acids 37-86 of SEQ ID NO. 303, wherein said first and second amino acid sequences are contiguous and in a sequential order;
• the polypeptide of SEQ ID NO:
• 414;
• the polypeptide of SEQ ID NO:
• 413;
• the polypeptide of SEQ ID NO:
• 412;
• the polypeptide of SEQ ID NO:
• 411;
• the polypeptide of SEQ ID NO:
• 410;
• the polypeptide of SEQ ID NO:
• 409;
• the polypeptide of SEQ ID NO:
• 408;
• the polypeptide of SEQ ID NO:
• 407;
• the polypeptide of SEQ ID NO:
• 406;
• the polypeptide of SEQ ID NO:
• 405;
• the polypeptide of SEQ ID NO:
• 404;
• the polypeptide of SEQ ID NO:
• 403;
• the polypeptide of SEQ ID NO:
• 402;
• the polypeptide of SEQ ID NO:
• 401;
• the polypeptide of SEQ ID NO:
• 400;
• the polypeptide of SEQ ID NO:
• 399;
• the polypeptide of SEQ ID NO:
• 398;
• the polypeptide of SEQ ID NO:
• 397;
• the polypeptide of SEQ ID NO:
• 396;
• the polypeptide of SEQ ID NO:
• 417;
• the polypeptide of SEQ ID NO:
• 416;
• the polypeptide of SEQ ID NO:
• 415;
• the polypeptide of SEQ ID NO:
• 420;
• the polypeptide of SEQ ID NO:
• 419;
• the polypeptide of SEQ ID NO:
• 418;
• the polypeptide of SEQ ID NO:
• 422;
• the polypeptide of SEQ ID NO:
• 421;
• the polypeptide of SEQ ID NO:
• 427;
• the polypeptide of SEQ ID NO:
• 426;
• the polypeptide of SEQ ID NO:
• 424;
• the polypeptide of SEQ ID NO:
• 423;
• the polypeptide of SEQ ID NO:
• 435;
• the polypeptide of SEQ ID NO:
• 395;
• the polypeptide of SEQ ID NO:
• 432;
• the polypeptide of SEQ ID NO:
• 394;
• the polypeptide of SEQ ID NO:
• 431;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise DP, having a structure as follows:
• a sequence starting from any of amino acid numbers 470−x to 470 of SEQ ID NO:332;
• and ending at any of amino acid numbers 471+((n−2)−x) of SEQ ID NO:332, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least three amino acids comprise VSI, having a structure as follows:
• a sequence starting from any of amino acid numbers 14−x to 14 of SEQ ID NO. 321;
• and ending at any of amino acid numbers 16+((n−2)−x) of SEQ ID NO. 321, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise IY, having a structure as follows:
• a sequence starting from any of amino acid numbers 115−x to 115 of SEQ ID NO:313;
• and ending at any of amino acid numbers 116+((n−2)−x) of SEQ ID NO:313, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise EL, having a structure as follows:
• a sequence starting from any of amino acid numbers 151−x to 151 of SEQ ID NO:
• 316;
• and ending at any of amino acid numbers 152+((n−2)−x) of SEQ ID NO:
• 316, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise DV, having a structure as follows:
• a sequence starting from any of amino acid numbers 140−x to 140 of SEQ ID NO:
• 287;
• and ending at any of amino acid numbers 141+((n−2)−x) of SEQ ID NO:
• 287, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least three amino acids comprise LDY having a structure as follows:
• a sequence starting from any of amino acid numbers 99−x to 99 of SEQ ID NO. 288;
• and ending at any of amino acid numbers 101+((n−2)−x) of SEQ ID NO. 288, in which x varies from 0 to n−2;
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least two amino acids comprise EE, having a structure as follows:
• a sequence starting from any of amino acid numbers 372−x to 372 of SEQ ID NO 293;
• and ending at any of amino acid numbers 373+((n−2)−x) of SEQ ID NO 293, in which x varies from 0 to n−2;
• and
• the isolated peptide having a length “n”, wherein n is selected from the group consisting of 10 amino acids in length, 20 amino acids in length, 30 amino acids in length, 40 amino acids in length and 50 amino acids in length, wherein at least at least two amino acids comprise AK, having a structure as follows:
• a sequence starting from any of amino acid numbers 8−x to 8 of SEQ ID NO:
• 302;
• and ending at any of amino acid numbers 9+((n−2)−x) of SEQ ID NO:
• 302, in which x varies from 0 to n−2.